Read by QxMD icon Read

International Journal of Clinical Oncology

Alireza Nazari, Hossein Khorramdelazad, Gholamhossein Hassanshahi
Following the publication from the original article, it came to our attention that we unintentionally neglected to acknowledge some text overlap with previous publications.
March 10, 2018: International Journal of Clinical Oncology
Hiroki Shirato
No abstract text is available yet for this article.
March 8, 2018: International Journal of Clinical Oncology
Toshifumi Yamaguchi, Ken Kato, Kengo Nagashima, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Tetsuya Hamaguchi, Yoshinori Ito, Jun Itami, Narikazu Boku, Kazuhide Higuchi
BACKGROUND: While the standard treatment for stage II-III (non-T4) esophageal squamous cell carcinoma (ESCC) is neoadjuvant therapy followed by esophagectomy, definitive chemoradiation therapy (dCRT) is an option to treat ESCC patients who reject or may not tolerate surgical treatment. Second primary malignancy (SPM) is a problem for long-term survivors after achieving complete response (CR) by dCRT. METHODS: The source of the subjects in this study was the patients with stage II/III (excluding T4 disease) ESCC (UICC6th) who underwent dCRT from 2000 to 2011 at the National Cancer Center Hospital, Japan...
March 8, 2018: International Journal of Clinical Oncology
Hiroki Nagai, Manabu Muto
Over the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develop resistance to these targeted therapies. Recently, immunotherapies such as immune checkpoint inhibitors have revolutionized the treatment paradigm for many types of malignancies. Immune checkpoint inhibitors have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, Hodgkin's lymphoma, bladder cancer and gastric cancer...
March 7, 2018: International Journal of Clinical Oncology
Kota Ouchi, Shin Takahashi, Sonoko Chikamatsu, Shukuei Ito, Yoshikazu Takahashi, Sadayuki Kawai, Akira Okita, Yuki Kasahara, Yoshinari Okada, Hiroo Imai, Keigo Komine, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Masanobu Takahashi, Makio Gamoh, Chikashi Ishioka
BACKGROUND: Recombinant human soluble thrombomodulin (rTM) has been established and introduced in the clinic as a standard treatment for disseminated intravascular coagulation (DIC). However, the efficacy and safety of rTM for DIC associated with solid tumors (DIC-STs) have not been fully established. Here, we performed a retrospective analysis of the clinical outcomes of rTM for DIC-STs and considered a treatment strategy with rTM for DIC-STs. METHODS: Patients with DIC-STs between November 2009 and March 2016 in 2 cancer core hospitals were retrospectively analyzed...
March 7, 2018: International Journal of Clinical Oncology
Fumitaka Ishige, Wataru Takayama, Satoshi Chiba, Isamu Hoshino, Hidehito Arimitsu, Hiroo Yanagibashi, Yosuke Iwatate
BACKGROUND: The prognosis of metastatic recurrent non-small cell lung cancer (NSCLC) is poor, and chemotherapy improves survival by only a few months. The concept of oligo-recurrence, defined as a small number of new lesions at a distant site theoretically curable by local therapy, has recently been proposed for several cancers. To evaluate the possible benefits of surgical resection for oligo-recurrence, we report the outcomes of seven patients who underwent hepatic resection for oligo-recurrence of NSCLC in the liver...
March 6, 2018: International Journal of Clinical Oncology
Miyuki Harada, Yutaka Osuga
An improvement in the survival rates of cancer patients and recent advancements in assisted reproductive technologies have led to remarkable progress in oncofertility and fertility preservation treatments. Currently, for adults and postpubertal girls, oocyte or embryo cryopreservation is an established method. If their cancer treatment cannot be postponed for 2 weeks, ovarian tissue cryopreservation is offered as an experimental technique. For prepubertal girls, ovarian tissue cryopreservation is the only option...
March 3, 2018: International Journal of Clinical Oncology
Marwan H Adly, Mohamed Sobhy, Mohamed A Rezk, Medhat Ishak, Mahmoud A Afifi, Ayman El Shafie, Mahmoud Ahmed Ali, Wael Zekri, Ahmad Samir Alfaar, Wafaa M Rashed
BACKGROUND: Thyroid carcinoma is a very rare tumor in the pediatric age group, accounting for only 1.5-3% of childhood carcinomas in the United States and Europe. We aimed to identify the risk of a second malignancy among pediatric thyroid cancer survivors. METHODS: The cohort analysis consisted of pediatric cancer patients aged less than 20 years, diagnosed with a primary thyroid cancer, identified by site code ICD-0-3: C739, and reported to the SEER 9 database between 1973 and 2013...
February 28, 2018: International Journal of Clinical Oncology
Hiroyuki Tsuchie, Makoto Emori, Hiroyuki Nagasawa, Naohisa Miyakoshi, Yasutaka Murahashi, Emi Mizushima, Toshihiko Yamashita, Yoichi Shimada
BACKGROUND: Soft tissue sarcoma (STS) mainly occurs in middle-aged and senior citizens. Although a poorer prognosis has been reported for older patients, few studies have examined advanced elderly excessive older patients. We evaluated the clinical features of advanced elderly patients with STS. METHODS: One hundred and forty-four patients were included in this retrospective study, and we divided them into two groups based on a cut-off age of 85 (older and younger groups)...
February 27, 2018: International Journal of Clinical Oncology
Takahiro Ando, Hidenori Kage, Minako Saito, Yosuke Amano, Yasushi Goto, Jun Nakajima, Takahide Nagase
BACKGROUND: Japanese Lung Cancer Society and ESMO guideline recommends screening for brain metastasis in all patients with non-small cell lung cancer (NSCLC), while NCCN/ACCP guidelines do not recommend screening patients who are asymptomatic and with clinical stage I NSCLC. However, brain metastasis sometimes occurs in early stage NSCLC patients without any neurological symptoms. METHODS: We retrospectively reviewed medical records of 124 patients admitted to the University of Tokyo Hospital with stage IV NSCLC from January 2012 to April 2016...
February 26, 2018: International Journal of Clinical Oncology
Taihei Oshiro, Keisuke Uehara, Toshisada Aiba, Toshiki Mukai, Tomoki Ebata, Masato Nagino
PURPOSE: Our sincere hope is to establish the predictive factors of neoadjuvant chemotherapy (NAC) response and provide patients with greater certainty regarding treatment outcomes. The aim of this study was to assess the response to NAC and survival in patients with locally advanced rectal cancer (LARC) according to their RAS/BRAF mutation status. METHODS: Data on 57 patients with LARC who received NAC between 2009 and 2016 were analyzed retrospectively. The patients were classified into two groups based on their mutation status: wild-type in both RAS and BRAF (WT) or mutant-type in either RAS or BRAF (MT)...
February 24, 2018: International Journal of Clinical Oncology
Hisashi Uhara
New therapeutic strategies including immunotherapy and selective molecular target inhibitors have brought about a new era in the treatment of patients with advanced melanoma. In Japan, the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab, the BRAF inhibitor (BRAFi) vemurafenib, dabrafenib and MEK inhibitor (MEKi) trametinib have been available for the treatment of unresectable and metastatic melanoma. The BRAFi + MEKi combination shows high response rates (60-70%) and rapid response induction associated with symptom control, with a progression-free survival of 12 months...
February 22, 2018: International Journal of Clinical Oncology
Hironaga Satake, Akihito Tsuji, Masato Nakamura, Masaaki Ogawa, Takeshi Kotake, Yukimasa Hatachi, Hisateru Yasui, Akinori Takagane, Yoshihiro Okita, Kumi Nakamura, Toshihide Onikubo, Masahiro Takeuchi, Masashi Fujii
BACKGROUND: FOLFOXIRI is now regarded as the chemotherapy regimen that offers the best platform for the treatment of colorectal cancer. However, the safety and efficacy of FOLFOXIRI + panitumumab has not been demonstrated. We conducted a phase I study to determine the recommended dose of FOLFOXIRI + panitumumab as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC). METHODS: Patients received combination therapy consisting of panitumumab (6 mg/kg on day 1) + FOLFOXIRI [irinotecan (CPT-11), oxaliplatin (L-OHP) 85 mg/m2 , and folinate (LV) 200 mg/m2 ] on day 1, followed by fluorouracil (5-FU) 3200 mg/m2 infused as a 46-h continuous infusion starting on day 1) repeated every 2 weeks as first-line treatment of RAS wild-type mCRC patients...
February 20, 2018: International Journal of Clinical Oncology
Mika Okazawa-Sakai, Takanori Yokoyama, Etsuko Fujimoto, Shinichi Okame, Yuko Shiroyama, Takashi Yokoyama, Kazuhiro Takehara
BACKGROUND: Taxane/platinum (TP)-based combination chemotherapy is standard for the treatment of metastatic or recurrent cervical cancer. The aim of this study was to investigate the efficacy of postoperative TP therapy in early stage cervical cancer. METHODS: A retrospective review of patients with FIGO IB-IIB stage cervical cancer who were treated with radical hysterectomy and displayed surgical-pathological risk factors was performed. 122 patients were identified between 2003 and 2012...
February 14, 2018: International Journal of Clinical Oncology
Yuri Taniguchi, Yoko Matsumoto, Ryutaro Furukawa, Sayaka Ohara, Kazuhiro Usui
BACKGROUND: The process of selecting patients on the basis of epidermal growth factor receptor (EGFR) mutations would likely result in a patient population with greater sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, EGFR mutation status is not routinely examined in patients with squamous cell lung cancer (Sq) because of the low incidence of EGFR mutations and the poor clinical response to EGFR-TKIs. METHODS: We retrospectively reviewed the clinical features of patients at our hospital with Sq who carried EGFR-TKI-sensitive EGFR mutations and assessed their responses to EGFR-TKIs...
February 14, 2018: International Journal of Clinical Oncology
Kunihisa Uchita, Kenji Kanenishi, Koki Hirano, Hideki Kobara, Noriko Nishiyama, Ai Kawada, Shintaro Fujihara, Emi Ibuki, Reiji Haba, Yohei Takahashi, Yuka Kai, Kenji Yorita, Hirohito Mori, Jun Kunikata, Naoki Nishimoto, Toshiyuki Hata, Tsutomu Masaki
BACKGROUND: Colposcopy, which is a standard modality for diagnosing cervical intraepithelial neoplasia (CIN), can have limited accuracy owing to poor visibility. Flexible magnifying endoscopy with narrow band imaging (ME-NBI) has excellent diagnostic accuracy for early gastrointestinal neoplasms and is expected to be highly useful for CIN diagnosis. This study aimed to determine the characteristic findings and evaluate the diagnostic ability of ME-NBI for lesions ≥ CIN 3. METHODS: A well-designed prospective diagnostic case series conducted at multiple tertiary-care centers...
February 14, 2018: International Journal of Clinical Oncology
Megumi Hirobe, Toshiaki Tanaka, Tetsuya Shindo, Koji Ichihara, Hiroshi Hotta, Atsushi Takahashi, Ryuichi Kato, Masahiro Yanase, Masanori Matsukawa, Naoki Itoh, Yasuharu Kunishima, Keisuke Taguchi, Hiroki Horita, Naoya Masumori
PURPOSE: We prospectively evaluated the 90-day postoperative mortality and morbidity of open radical cystectomy by using a standardized reporting methodology. Additionally, we assessed the preoperative characteristics to determine risk factors for major complications. METHODS: This multicenter prospective study included 185 consecutive patients undergoing open radical cystectomy from October 2010 through March 2014. Postoperative complications within 90 days were recorded and graded according to the modified Clavien-Dindo classification...
February 13, 2018: International Journal of Clinical Oncology
Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku Nomura
BACKGROUND: There is an unmet need to identify markers that predict the response to nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR) was recently recognized as an indicator of a poor prognosis in patients with various cancers. In the present study, we quantified the predictive impact of NLR in patients with NSCLC treated with nivolumab. METHODS: We retrospectively analyzed 101 patients with advanced NSCLC treated with nivolumab at Kansai Medical University Hospital from December 2015 to December 2016...
February 13, 2018: International Journal of Clinical Oncology
Koichi Kido, Shingo Hatakeyama, Naoki Fujita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Ikuya Iwabuchi, Masaru Ogasawara, Toshiaki Kawaguchi, Chikara Ohyama
BACKGROUND: Oncologic benefits of laparoscopic radical nephroureterectomy (LNU) are unclear. We aimed to evaluate the impact of surgical approach for radical nephroureterectomy on oncologic outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC). METHODS: Of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017, we retrospectively investigated oncological outcomes in 229 with locally advanced UTUC (stages cT3-4 and/or cN+)...
February 12, 2018: International Journal of Clinical Oncology
Kuai-Le Zhao, Yi Xia, Yun-Hai Li, Yun Chen, Qi Liu, Jun-Hua Zhang, Jia-Ying Deng, Ta-Shan Ai, Han-Ting Zhu, Harun Badakhshi
BACKGROUND: This study was performed to assess the efficacy and feasibility of definitive chemoradiotherapy consisting of weekly doses of combined paclitaxel and carboplatin concurrent with radiation therapy, followed by 2 cycles of consolidation chemotherapy for advanced esophageal carcinoma. METHODS: Eligibility criteria included local, advanced, newly diagnosed and postoperative local regional lymph node metastasis; Eastern Cooperative Oncology Group (ECOG) score ≤ 2; and adequate organ function...
February 12, 2018: International Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"